George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They've consistently said they expect to fund expansion with current capital base, so I hope no rights issue, and would rather see debt fall over next couple of years.
No bad surprises in the trading update and the SP should see a significant improvement from next month.
Happy New Year to all holders
Totally agree. Need elections out of the way, despots to stop trying to grab land and power and the world to come to its senses. Next update critical - if continuing to grow turn-over and hopefully maiden profit - given the demand for their products this share will in my view rapidly rise. All is in place - just one last rights issue/loan for further expansion next year and this could very possible triple or better in the next two years - lots of ifs and of course it could go the other way
Hello spindok
The general trend with AIM companies at the moment seems to be that those that are trading well just have a static SP.
With the rest of the market also in the doldrums, I think we need to see an improvement in the FTSE100 and 250 before AIM picks up.
Happy new year.
This is an action packed investment. It went bloo.. Enjoy the new year..
I think we need to see a general rise in small cap AIM stocks before we see an appreciable rise here.
There seems to be a good number of very good little companies that trade on AIM that have been held down by the general gloom surrounding the whole market - mainly because of high interest rates.
Hopefully 2024 will be about identifying these opportunities, sorting the wheat from the chaff, and capitalising on them.
There is usually a trading statement in January ahead of full year results
@jimjam Why should it become clearer in January? Results not before March, surely. Have I missed something?
The stickiest, plus rather than just holding, they continue to accumulate 😉
Yes, this one never fails to disappoint. It was higher than this pre consolation, can’t get past 57 now. I think when it does it will a nice rise. When is another question.
HNY everyone.
Yes and to all lths - will keep these for many years to come
Never know what is going on in the background but they are setting up for a bright future - just need that first year of profit not ebita profit - then further expansion and right to sell in the many countries they have applications in for and should be a bright future
Hold a fair few aim shares, our directors stand apart - have faith in them to deliver
I'm here for the long term but don't know why the share is not doing better. Surely we should be nearer to 80 right now. Oh well it will become clearer in January. Enjoy your Christmas. JJ
I Agree. Something I have always stipulated.
I'm very positive on this company's prospects. If the Trading Updates keep showing that positive upward trajectory into profitability then the re-rate will be big.
But someone seems desperate for a bit of Xmas cash this morning...
Yes same to you - next couple of years should be the making of this company
Hopefully...
I don't think that would be an unreasonable reflection of the business worth and progress and foundations in place...but there would have to be a major increase in awareness and interest in the share too, to generate some volume. Anyhow seasons greetings to all holders, and best wishes for new year. Hope it's a good one
Very sticky shareholders here. They buy and they hold. January figures should be excellent.. After a year of no ovement this may jump a 100%
Interesting, thank you for posting this.
Still daily sells but no movement in SP (he says tempting fate!) - as before must be buyer in the background - in my amateurish view
Conclusions:
In conclusion, of the 27 clinical trials of decellularized tissue in orthopaedics identified by a comprehensive survey, nine were completed. Despite the demand for decellularized tissue, not many decellularized tissue products are commercially available now, particularly for the knee joint. However, the variety of available decellularized products, including OrthoPure XT for knee surgery, has recently increased. Therefore, decellularized grafts may become a promising option in orthopaedic surgery.
A good read, thank you for posting.
Lombard Odier as it turns out
S&N has just agreed to buy Cartiheal for £144m payable now and a further £120m subject to achieving annual sales of $100m pa within 10 years. Cartiheal only got FDA approval last year for Agili-C and will have modest current sales. Does anyone with knowledge of Orthopaedics know whether Agili-C is new competition for dCell and BioRinse in the orthopaedics space or whether they do different things? Not sure whether to take the S&N purchase as evidence of the significant under value of TRX or a competition risk to TRX, or both.
I think the deal was that king sung would pay regulatory costs. I think further local trials were needed as part of this process, hence in terms of timing for approval I anticipated years rather than months. Re question I've seen no update on progress. There was also a minimum annual order clause I think, but that presumably starts small.
King Sung is the company that Tissue Regenix signed a distribution agreement in China with...
This is the Tissue Regenix board me ole mucka , how would we know? Maybe post on the relevant chat board.